Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,139.0
-18.1 (-0.57%)

 

  • STI Straits Times Index
    3,139.0
    -18.1 (-0.57%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,512.5
    -10.9 (-0.72%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,192.3
    -1,129.7 (-4.13%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,467.4
    -83.0 (-2.34%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    27,833.3
    285.3 (1.04%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,106.4
    4.7 (0.08%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,058.1M
  • Value: 970.5M
  • Rise: 151
  • Fall: 191
  • Unch: 419

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Thomson Medical0.088+0.003
Jiutian Chemical0.084-0.001
Sembcorp Marine0.104+0.001
Spackman0.005-
Accrelist Ltd0.072+0.015
Oceanus^0.036-
Abundance Intl0.040+0.001
ThaiBev0.655-0.005
SPH1.860+0.010
Rex Intl0.205-

World Indices

World Indices
Name Last Change
Nasdaq 14,840.7 +3.7
HSI 26,192.3
HSCEI 9,355.2
Jakarta 6,106.4
Nikkei 225 27,833.3
SSE Comp 3,467.4
Shanghai A 3,634.2
Shanghai B 260.4
KOSPI 3,224.9

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Lonza LONZA GROUP LTD
Quotes 10 Minutes Delayed. Updated at 26 Jul 2021 07:12
Last (SGD): 79.970 Change: - High: - Remarks: -
Change (%): - Low: -
Open - Yesterday's Close 79.970
Buy Price - Sell Price -
Buy Volume ('000) - Sell Volume ('000) -
Cumulative Volume ('000) - Cumulative Value -
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a 17.53723 Trailing EPS (SGD) e 14.40184 NAV (SGD) b 142.7612
PE a 4.560 Trailing PE f 5.553 Price / NAV b 0.5602
Dividend (SGD) d 4.497663 Cash In Hand (SGD) g 9.8422 Issued & Paid-up Shares c 74,283,000
Dividend Yield (%) d 5.624 Price / Cash In Hand g 8.125 Treasury Shares h 186,000
Beta - 75 Daysi - R-Squared - 75 Days(%)i - Market Cap (M) 5,940.412
Beta - 500 Daysi - R-Squared - 500 Days (%)i - Enterprise Value (M) 10,637.899
Piotroski F Score 6 Exchange Code O6Z Par Value ( CHF ) 1.00000
52 Weeks Volatility (%) 0.0 6-Month VWAP n.a. Free Float (%) 99.9
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Manufacturing - Biotechnology
Category Classification Foreign Listing (Others) / Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 28 Jun 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 28 Jun 2021.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Lonza SGX 5,940.412 4.560 5.553 0.5602 5.624
Industry Biotechnology SGX 2,991.858 4.593 4.593 0.5633 5.583
Foreign Listing (Others) SGX 8,122.147 23.423 14.654 1.8911 1.674
Medical & Biotechnology SGX 970.173 20.347 17.265 1.3954 1.986
Local Peer Suntar Eco-City SGX 43.304 1725.000 1732.189 2.3917 -
Global Peer AMGEN INC NASDAQ 142,328.517 19.594 20.089 15.2484 2.600
Global Peer MODERNA INC NASDAQ 140,065.012 - 234.157 36.4942 -
Global Peer AMGEN-T HKEx 1,011,789.594 17.959 18.421 13.9429 2.837
Global Peer CSL LTD ASX 133,220.810 42.477 35.005 12.6068 1.002
Global Peer GILEAD SCIENCES INC NASDAQ 86,563.504 703.783 287.586 4.5675 3.940
Global Peer ILLUMINA INC NASDAQ 72,344.460 110.281 114.832 14.6982 -
Global Peer BIONTECH SE SPON ADS EACH REP 1 ORD SHS NASDAQ 68,099.261 3,930.852 46.852 22.9965 -
Global Peer WUXI BIO HKEx 490,284.673 258.347 258.345 20.1083 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 62,472.057 17.782 15.603 5.2160 -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 51,902.633 19.141 18.791 5.7796 -
Other Global Peers BIOGEN INC (NASDAQ), ALEXION PHARMACEUTICAL INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), BEIGENE (HKEx), SEAGEN INC (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), EXACT SCIENCES CORP (NASDAQ), 10X GENOMICS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), INCYTE CORPORATION (NASDAQ), SINO BIOPHARM (HKEx), NOVAVAX INC (NASDAQ), ZAI LAB-SB (HKEx), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), BRIDGEBIO PHARMA INC (NASDAQ), GENSCRIPT BIO (HKEx), FATE THERAPEUTICS (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), RECURSION PHARMACEUTICALS INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), BEAM THERAPEUTICS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), EXELIXIS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), ARVINAS INC (NASDAQ), JOINN (HKEx), OLINK HLDG AB SPON ADS EACH REP 1 ORD SHS (NASDAQ), KODIAK SCIENCES INC (NASDAQ), ABCELLERA BIOLOGICS INC (NASDAQ), ABCAM PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), ALKERMES PLC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), LYELL IMMUNOPHARMA INC (NASDAQ), SANA BIOTECHNOLOGY INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), KINTOR PHARMA-B (HKEx), ALLOGENE THERAPEUTICS INC (NASDAQ), RELAY THERAPEUTICS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), KYMERA THERAPEUTICS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), INSMED INC (NASDAQ), ALPHAMAB-B (HKEx), VERACYTE INC (NASDAQ), ALECTOR INC (NASDAQ), INSTIL BIO INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), 3SBIO (HKEx), PROTHENA CORP PLC (NASDAQ), ZENTALIS PHARMACEUTICALS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), SEER INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), HAOHAI BIOTEC (HKEx), DECIPHERA PHARMACEUTICALS INC (NASDAQ), ORGANOGENESIS HOLDINGS INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), JACOBIO-B (HKEx), CORTEXYME INC (NASDAQ), VIVA BIOTECH (HKEx), NUVATION BIO INC (NYSE), XENCOR INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), C4 THERAPEUTICS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), FRONTAGE (HKEx), ASCENTAGE-B (HKEx), PRELUDE THERAPEUTICS INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), MACROGENICS INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), REGENXBIO INC (NASDAQ), COMPASS PATHWAYS PLC UNSPON ADS REP 1 ORD SHS (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), IMMUNOCORE HLDGS PLC SPON ADS EACH REP ONE ORD SHS (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), GRAPHITE BIO INC (NASDAQ), BIOATLA INC (NASDAQ), VALNEVA SE SPON ADS EACH REPR 2 ORD SHS (NASDAQ), OCUGEN INC (NASDAQ), PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS (NASDAQ), MIMEDX GROUP INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), APPLIED MOLECULAR TRANSPORT INC (NASDAQ), IMUGENE LIMITED (ASX), AGENUS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), FIBROGEN INC (NASDAQ), ALLOVIR INC (NASDAQ), JANUX THERAPEUTICS INC (NASDAQ), UNIQURE N.V. (NASDAQ), VAXCYTE INC (NASDAQ), NAUTILUS BIOTECHNOLOGY INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), POLYNOVO LIMITED (ASX), PRECIGEN INC (NASDAQ), IMMUNOGEN INC (NASDAQ), TELIX PHARMACEUTIC (ASX), INHIBRX INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), JW THERAP-B (HKEx), NKARTA INC (NASDAQ), MONTE ROSA THERAPEUTICS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), DYNE THERAPEUTICS INC (NASDAQ), VAXART INC (NASDAQ), EDGEWISE THERAPEUTICS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), IMMUNOVANT INC (NASDAQ), HUMANIGEN INC (NASDAQ), MESOBLAST LTD (ASX), PERSONALIS INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), JHBP-B (HKEx), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), SHATTUCK LABS INC (NASDAQ), IVERIC BIO INC (NASDAQ), PLIANT THERAPEUTICS INC (NASDAQ), OMEROS CORP (NASDAQ), ITEOS THERAPEUTICS INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), CARIBOU BIOSCIENCES INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), AVIDITY BIOSCIENCES INC (NASDAQ), AFFIMED N V (NASDAQ), AMBRX BIOPHARMA INC SPON ADS EACH REP 7 ORD SHS (NYSE), GRACELL BIOTECHNOLOGIES INC SPON ADS EACH REP 5 ORD SHS (NASDAQ), TRAVERE THERAPEUTICS INC (NASDAQ), SUMMIT THERAPEUTICS INC (NASDAQ), IMMATICS N V (NASDAQ), RADIUS HEALTH INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), KADMON HLDGS INC (NASDAQ), TAYSHA GENE THERAPIES INC (NASDAQ), EPIZYME INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), MERUS B V (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), PASSAGE BIO INC (NASDAQ), CURIS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), SESEN BIO INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), 4D MOLECULAR THERAPEUTICS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), MOLECULAR PARTNERS AG SPON ADS EACH REP 1 ORD SHS (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), CHIMERIX INC (NASDAQ), AKOYA BIOSCIENCES INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), VERASTEM INC (NASDAQ), ACTINIUM PHARMACEUTICALS INC (NYSE American), ADAPTIMMUNE THERAPEUTICS PLC SPON ADS EACH REP 6 ORD SHS (NASDAQ), COMPUGEN (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), ASPIRA WOMENS HEALTH INC (NASDAQ), GREENWICH LIFESCIENCES INC (NASDAQ), POSEIDA THERAPETUICS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), IMAGO BIOSCIENCES INC (NASDAQ), INVENTIVA SA SPON ADS EACH REP 1 ORD SHS (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), ESSEX BIO-TECH (HKEx), CLOVIS ONCOLOGY INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), VOR BIOPHARMA INC (NASDAQ), DPHARMA (Bursa), XBIOTECH INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), RAIN THERAPEUTICS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), LANDOS BIOPHARMA INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), ASCLETIS-B (HKEx), OUTLOOK THERAPEUTICS INC (NASDAQ), GERON CORP (NASDAQ), FORTE BIOSCIENCES INC (NASDAQ), SINOMAB BIO-B (HKEx), AKOUOS INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), VIRACTA THERAPEUTICS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), IKENA ONCOLOGY INC (NASDAQ), SQZ BIOTECHNOLOGIES CO (NYSE), ATHIRA PHARMA INC (NASDAQ), VERA THERAPEUTICS INC. (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), INMUNE BIO INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), FOGHORN THERAPEUTICS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), OPTHEA LIMITED (ASX), BIOVIE INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), ALTIMMUNE INC (NASDAQ), ATHERSYS INC (NASDAQ), NEOLEUKIN THERAPEUTICS INC (NASDAQ), OPTHEA LIMITED SPON ADS EACH REPR 8 ORD SHS (NASDAQ), BLACK DIAMOND THERAPEUTICS INC (NASDAQ), ONCORUS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), ANTEOTECH LIMITED (ASX), HARVARD BIOSCIENCE INC (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), LEE'S PHARM (HKEx), AVROBIO INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), AEROVATE THERAPEUTICS INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), IMMUTEP LTD (ASX), CYMABAY THERAPEUTICS INC (NASDAQ), 9 METERS BIOPHARMA INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), CHIASMA INC (NASDAQ), NANOVIRICIDES INC (NYSE American), ARBUTUS BIOPHARMA CORP (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), ATRECA INC (NASDAQ), ADICET BIO INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), ENOCHIAN BIOSCIENCES INC (NASDAQ), COGENT BIOSCIENCES INC (NASDAQ), KAMADA LTD (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), NEXT SCIENCE LTD (ASX), TREVENA INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), SENSEI BIOTHERAPEUTICS INC (NASDAQ), SPRUCE BIOSCIENCES INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), PORTAGE BIOTECH INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), TERNS PHARMACEUTICALS INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), ELEVATION ONCOLOGY INC (NASDAQ), LAVA THERAPEUTICS NV (NASDAQ), IMMUNOME INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), LARIMAR THERAPEUTICS INC (NASDAQ), MIROMATRIX MEDICAL INC (NASDAQ), CHEMOMAB THERAPEUTICS LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), NEXTCURE INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), HCW BIOLOGICS INC (NASDAQ), MARKER THERAPEUTICS INC (NASDAQ), MEDICINOVA INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), FREELINE THERAPEUTICS HLDGS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), DECIBEL THERAPEUTICS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), CABALETTA BIO INC (NASDAQ), SYNLOGIC INC (NASDAQ), SIGILON THERAPEUTICS INC (NASDAQ), ARDELYX INC (NASDAQ), SIO GENE THERAPIES INC (NASDAQ), IMMUNOPRECISE ANTIBODIES LTD (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), EQUILLIUM INC (NASDAQ), CONTRAFECT CORP (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), ENZO BIOCHEM INC (NYSE), SAVARA INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), VIRIDIAN THERAPEUTICS INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), VASCULAR BIOGENICS LTD (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), ANIXA BIOSCIENCES INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), ORGENESIS INC (NASDAQ), BIONOMICS LTD (ASX), MEDICENNA THERAPEUTICS CORP (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), IBIO INC (NYSE American), VOYAGER THERAPEUTICS INC (NASDAQ), LONGEVERON INC (NASDAQ), INFLARX N V (NASDAQ), EVOGENE LTD (NASDAQ), CHECKMATE PHARMACEUTICALS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), LEAF RESOURCES LTD (ASX), CAPRICOR THERAPEUTICS INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), IMV INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), GAIN THERAPEUTICS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), EVAXION BIOTECH AS SPON ADS EACH REP 1 ORD SHS (NASDAQ), OTONOMY INC (NASDAQ), BIOMX INC (NYSE American), ARMATA PHARMACEUTICALS INC (NYSE American), DYADIC INTERNATIONAL INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), AIM IMMUNOTECH INC (NYSE American), BON NAT LIFE LTD (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), UNI-BIO GROUP (HKEx), RECRO PHARMA INC (NASDAQ), AZIYO BIOLOGICS INC (NASDAQ), ARAVIVE INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), METACRINE INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), AIKIDO PHARMA INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), CHIMERIC THERAPEUTICS LTD (ASX), CELYAD ONCOLOGY SPON ADS EACH REPR 1 ORD SHS (NASDAQ), CEL-SCI CORP (NYSE American), ATYR PHARMA INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), COHBAR INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), PRECIPIO INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), BRIACELL THERAPEUTICS CORP (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), PATRYS LIMITED (ASX), VACCINEX INC (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), LUMOS PHARMA INC (NASDAQ), BIOCARDIA INC (NASDAQ), GENETIC TECHNOLOGIES (ASX), ALIMERA SCIENCES INC (NASDAQ), ADVAXIS INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), CELLECTAR BIOSCIENCES INC (NASDAQ), INDIA GLOBALIZATION CAPITAL INC (NYSE American), CYCLO THERAPEUTICS INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), MICROBOT MEDICAL INC (NASDAQ), CYCLACEL PHARMACEUTICALS INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), CT ENTERPRISE (HKEx), KIROMIC BIOPHARMA INC (NASDAQ), WINDTREE THERAPEUTICS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), ENDURANCE RP (HKEx), BIO-PATH HOLDINGS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), ANPAC BIO MEDICAL SCIENCE CO LTD SPON ADS EACH REPR 1 ORD SHS CLASS A (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), APPLIED DNA SCIENCES INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), TRANSCODE THERAPEUTICS INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), SOLIGENIX INC (NASDAQ), LIXTE BIOTECHNOLOGY HOLDINGS INC (NASDAQ), RHINOMED LIMITED (ASX), MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD SHS(R/S) (NASDAQ), MEMPHASYS LTD (ASX), TERRAGEN HOLDINGS LIMITED (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), ADITX INC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), HISTOGEN INC (NASDAQ), ZIVO BIOSCIENCE INC (NASDAQ), BIOTRON (ASX), ORAGENICS INC (NYSE American), BENITEC BIOPHARMA INC (NASDAQ), AVECHO BIOTECHNOLOGY LTD (ASX), BIOSINO BIO-TEC (HKEx), GEOVAX LABS INC (NASDAQ), SONNET BIOTHERAPEUTICS HLDGS INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), PALISADE BIO INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), AMPLIA THERAPEUTICS LTD (ASX), SENESTECH INC (NASDAQ), REGENEUS LTD (ASX), ADALTA LTD (ASX), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), CONSTELLATION TECHNOLOGIES LTD (ASX), CRYOSITE (ASX), HOLISTA COLLTECH LIMITED (ASX), ARGENICA THERAPEUTICS LIMITED (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), NANOLLOSE LTD (ASX), ANATARA LIFESCIENCES LTD (ASX), HAO WEN HLDGS (HKEx), LIVING CELL TECHNOLOGIES (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

Not enough data to show total shareholder returns
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 79.970 - 79.970 Change From 1 Year Low - % Change From 1 Year Low (%) -
Change From 1 Year High - % Change From 1 Year High (%) -
2 Years Range 79.970 - 79.970 Change From 2 Years Low - % Change From 2 Years Low (%) -
Change From 2 Years High - % Change From 2 Years High (%) -
5 Years Range 79.970 - 79.970 Change From 5 Years Low - % Change From 5 Years Low (%) -
Change From 5 Years High - % Change From 5 Years High (%) -
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Lonza Group Ltd is a corporation incorporated under the laws of Switzerland and has been listed on the SIX Swiss Exchange (the “SIX”) since November 1999.Lonza is a supplier to the pharmaceutical, healthcare and life sciences industries with products and services spanning from research to final product manufacture to meet customers' needs. The products Lonza manufacture for the life sciences industry can be characterised as very complex molecules which are manufactured in a highly regulated environment and will end up in the body of human beings or animals.Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. The Group has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. The Group provides cell-based research, endotoxin detection and cell therapy manufacturing. The Group is also a provider of high value chemicals and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.To provide optimal support to its customers, the Group is organized into three business divisions, namely, Custom Manufacturing, Life Science Ingredients and Bioscience, which focus on specific sets of customers and their needs.

IPO Performance

Listing Date 21 Oct 2011 Full Subscription Rate (x) -
No of Placement Shares (M) - No of Public Offer Shares (M) - Public Offer Subscription Rate (x) -
IPO Price (SGD) a - First Day Close (SGD) a 79.970 First Week Close (SGD) a 79.970
Current vs IPO Price (%) - First Day Gain (%) - First Week Gain (%) -
Notes:
  1. Adjusted for the following: IPO Price is not available as there are no issue of Shares under the Listing by way of Introduction.

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2020 Dec 2020 Part 1(0.46 MB)
Part 2(13.07 MB)
Annual Report 2019 Dec 2019 Part 1(0.15 MB)
Part 2(18.45 MB)
Annual Report 2018 Dec 2018 Part 1(7.67 MB)
Annual Report 2017 Dec 2017 Part 1(10.98 MB)
Annual Report 2016 Dec 2016 Part 1(7.93 MB)
Annual Report 2015 Dec 2015 Part 1(1.90 MB)
Part 2(2.28 MB)
Annual Report 2014 Dec 2014 Part 1(3.90 MB)
Part 2(6.06 MB)
Annual Report 2013 Dec 2013 Part 1(3.42 MB)
Annual Report 2012 Dec 2012 Part 1(3.87 MB)
Annual Report 2011 Dec 2011 Part 1(5.01 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
26 Jul 2021 79.970 79.970 79.970 79.970 - -
23 Jul 2021 79.970 79.970 79.970 79.970 - -
22 Jul 2021 79.970 79.970 79.970 79.970 - -
21 Jul 2021 79.970 79.970 79.970 79.970 - -
19 Jul 2021 79.970 79.970 79.970 79.970 - -
16 Jul 2021 79.970 79.970 79.970 79.970 - -
15 Jul 2021 79.970 79.970 79.970 79.970 - -
14 Jul 2021 79.970 79.970 79.970 79.970 - -
13 Jul 2021 79.970 79.970 79.970 79.970 - -
12 Jul 2021 79.970 79.970 79.970 79.970 - -
09 Jul 2021 79.970 79.970 79.970 79.970 - -
08 Jul 2021 79.970 79.970 79.970 79.970 - -
07 Jul 2021 79.970 79.970 79.970 79.970 - -
06 Jul 2021 79.970 79.970 79.970 79.970 - -
05 Jul 2021 79.970 79.970 79.970 79.970 - -
02 Jul 2021 79.970 79.970 79.970 79.970 - -
01 Jul 2021 79.970 79.970 79.970 79.970 - -
30 Jun 2021 79.970 79.970 79.970 79.970 - -
29 Jun 2021 79.970 79.970 79.970 79.970 - -
28 Jun 2021 79.970 79.970 79.970 79.970 - -
25 Jun 2021 79.970 79.970 79.970 79.970 - -
24 Jun 2021 79.970 79.970 79.970 79.970 - -
Summary
Current 2 Weeks
(12 Jul 2021 to 26 Jul 2021)
79.970 79.970 79.970 79.970 - -
Previous 2 Weeks
(28 Jun 2021 to 09 Jul 2021)
79.970 79.970 79.970 79.970 - -
4 Weeks from
(31 May 2021 to 25 Jun 2021)
79.970 79.970 79.970 79.970 - -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.